At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
DFTX Definium Therapeutics
Market Closed 03-27 16:00:00 EDT
17.88
-1.06
-5.60%
盘后17.88
+0.000.00%
19:42 EDT
High18.84Low17.66Vol1.74M
Open18.83D1 Closing18.94Amplitude6.23%
Mkt Cap1.78BTradable Cap1.68BTotal Shares99.70M
T/O31.41MT/O Rate1.86%Tradable Shares93.74M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Definium Therapeutics to host Investor and Analyst Day; DT120 ODT Phase 3 program to be highlighted
Reuters  ·  03-26 19:00
Definium Therapeutics to host Investor and Analyst Day; DT120 ODT Phase 3 program to be highlighted
A Look At Definium Therapeutics (DFTX) Valuation After Strong Recent Share Price Momentum
Simply Wall St.  ·  03-21
A Look At Definium Therapeutics (DFTX) Valuation After Strong Recent Share Price Momentum
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX), Integer Holdings (ITGR) and Edgewise Therapeutics (EWTX)
TIPRANKS  ·  03-11
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX), Integer Holdings (ITGR) and Edgewise Therapeutics (EWTX)
Definium Therapeutics issues inducement equity grants of 134,540 options and 34,500 PSUs
Reuters  ·  03-10
Definium Therapeutics issues inducement equity grants of 134,540 options and 34,500 PSUs
Stock Track | Definium Therapeutics Soars 5.24% Intraday on Analyst Buy Rating and $26 Price Target
Stock Track  ·  03-04
Stock Track | Definium Therapeutics Soars 5.24% Intraday on Analyst Buy Rating and $26 Price Target
Evercore ISI Sticks to Their Buy Rating for Definium Therapeutics (DFTX)
TIPRANKS  ·  03-03
Evercore ISI Sticks to Their Buy Rating for Definium Therapeutics (DFTX)
Definium Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  03-02
Definium Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Definium Therapeutics (DFTX) Receives a Buy from H.C. Wainwright
TIPRANKS  ·  03-02
Definium Therapeutics (DFTX) Receives a Buy from H.C. Wainwright
Definium Therapeutics Advances DT120 ODT As Trials And Valuation Gain Focus
Simply Wall St.  ·  03-01
Definium Therapeutics Advances DT120 ODT As Trials And Valuation Gain Focus
Canaccord Genuity Remains a Buy on Definium Therapeutics (DFTX)
TIPRANKS  ·  02-27
Canaccord Genuity Remains a Buy on Definium Therapeutics (DFTX)
Definium Therapeutics: Late-Stage Pipeline Progress and Upcoming Phase 3 Readouts Support Buy Rating and Favorable Risk-Reward
TIPRANKS  ·  02-27
Definium Therapeutics: Late-Stage Pipeline Progress and Upcoming Phase 3 Readouts Support Buy Rating and Favorable Risk-Reward
Definium Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Reuters  ·  02-27
Definium Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Definium Therapeutics Inc. Publishes Corporate Presentation on DT120 ODT Phase 3 Programs for GAD and MDD
Reuters  ·  02-27
Definium Therapeutics Inc. Publishes Corporate Presentation on DT120 ODT Phase 3 Programs for GAD and MDD
Definium Therapeutics Q4 EPS $(0.50) Misses $(0.46) Estimate.
Benzinga  ·  02-27
Definium Therapeutics Q4 EPS $(0.50) Misses $(0.46) Estimate.
Definium Therapeutics FY 2025 R&D expenses rise 80.2% to USD 117.7 million
Reuters  ·  02-27
Definium Therapeutics FY 2025 R&D expenses rise 80.2% to USD 117.7 million
Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates
THOMSON REUTERS  ·  02-27
Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates
Definium Therapeutics - $411.6 Million in Cash, Cash Equivalents and Investments as of December 31, 2025 Expected to Fund Operations Into 2028
THOMSON REUTERS  ·  02-27
Definium Therapeutics - $411.6 Million in Cash, Cash Equivalents and Investments as of December 31, 2025 Expected to Fund Operations Into 2028
JonesTrading Remains a Buy on Definium Therapeutics (DFTX)
TIPRANKS  ·  02-25
JonesTrading Remains a Buy on Definium Therapeutics (DFTX)
Definium Therapeutics Initiated at Outperform by Wolfe Research
Dow Jones  ·  02-24
Definium Therapeutics Initiated at Outperform by Wolfe Research
Press Release: Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026
Dow Jones  ·  02-20
Press Release: Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026

Introduction

Company Name.
Definium Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company also develops MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. The company is headquartered in New York, New York.
Issue price:
--